Navigation Links
Solos Endoscopy, Inc. Reports $90,005 in Sales Revenue for Fourth Quarter 2010
Date:1/27/2011

BOSTON, Jan. 27, 2011 /PRNewswire/ -- Solos Endoscopy, Inc. (OTCPK: SNDY) is pleased to announce that the Company generated revenues during the three months ended December 31, 2010 in the amount of $90,005. The revenue for the three month period is a result of instrument sales to over fifty Hospitals, Clinics, Healthcare Centers, Medical Centers and Surgery Centers across the United States.

Solos looks towards continued growth in 2011 through new product development, new product sales and the completion of the requirements for the Company's ISO 13485 quality management system (QMS) initiative. The ISO QMS initiative is a major step in obtaining the CE Mark and the permission to sell medical devices in the European Union. Solos recently announced the approval of its 2011 recapitalization plan, which allows greater flexibility to utilize the assets of the Company to raise the necessary capital to achieve the aforementioned goals.

"As an innovative HealthCare instrument company, Solos continues to position itself to take advantage of the ever increasing demand of the medical industry," stated Bob Segersten, President of Solos Endoscopy, Inc. "Our portfolio is centered on instruments like the MammoView Breast Endoscopy System that are designed to support a wide range of options from screening and diagnosis, to treatment and management of medical conditions."

The Company expects to post its full unaudited financial results for the three months ended December 31, 2010 on the OTC Markets Group website within in the next sixty days.

About Solos Endoscopy, Inc.:

Solos Endoscopy, Inc. is a HealthCare instrument company whose mission is to develop and market high quality and innovative instruments for the screening, diagnosis, treatment and management of medical conditions. Additional information on its FDA approved products is available on the Company's website at:

SOURCE Solos Endoscopy, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Solos Endoscopy, Inc. Trends toward Strong Continued Growth in 2011
2. Solos Endoscopy, Inc. Announces Recapitalization Plan for 2011
3. Solos Endoscopy, Inc. Revenue Grows 34.8% for Third Quarter 2010
4. Solos Endoscopy, Inc. Announces Results of 2010 Annual Shareholder Meeting
5. Solos Endoscopy, Inc. to Hold Annual Shareholder Meeting September 28, 2010
6. Solos Endoscopy, Inc. Develops Relay Lense Adapter System For MammoView® Product Line
7. Solos Endoscopy, Inc. Increases Revenues by 10 Percent for First Quarter 2010 as Compared to First Quarter 2009
8. Solos Endoscopy, Inc. Appoints Experienced CFO To Financial Leadership Amidst Growth
9. Solos Endoscopy, Inc. Granted U.S. Trademark for MammoView(R)
10. Solos Endoscopy, Inc. Set To Develop European Union Conforming CE Mark Technical File
11. Solos Endoscopy, Inc. Set To Develop New Polymer Dilator For MammoView(TM) System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014  Zafgen, Inc., a leading biopharmaceutical company dedicated ... patients, today announced initial results from its Phase ... methionine aminopeptidase 2 (MetAP2), in patients with Prader-Willi ...  These results showed improvements in body weight, hunger-related ...
(Date:1/14/2014)... 14, 2014 HeartWare International, Inc . (NASDAQ: ... invasive, miniaturized circulatory support technologies that are revolutionizing the ... expects revenues for the fourth quarter of 2013 will ... to approximately $208 million. "Our full-year revenue ...
(Date:1/14/2014)... Jan. 14, 2014 InformEx, North America,s ... high-value chemistry, will hold the 30 th edition of ... Convention Center from January 21-24. (Logo: ... top pharmaceutical, fine chemical and specialty chemical companies will take ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
... Be a More Effective Monitor Than, Hemoglobin A1C of ... ... FRANCISCO, June 7 GlycoMark, Inc. announced today,results from ... test is a better reflection of glucose, particularly after-meal,glucose ...
... SAN FRANCISCO, California, June 6 , - ... results from the world,s largest ever study of ... using modified release,gliclazide and other drugs as required, ... particular, intensive treatment reduces,the risk of kidney disease ...
Cached Medicine Technology:DURABLE Clinical Trial Results Show GlycoMark is Key Test for Managing Patients with Diabetes 2DURABLE Clinical Trial Results Show GlycoMark is Key Test for Managing Patients with Diabetes 3The Largest Ever Study of Diabetes Shows Intensive Glucose Control Reduces Serious Complications 2
(Date:7/9/2014)... OH, July 10, 2014 -- The World Health Organization ... minutes of moderate to vigorous physical activity (MVPA) each ... of their MVPA during school hours. Therefore, it ... hours would increase MVPA. In a new study ... , researchers confirmed that time spent outdoors after school ...
(Date:7/9/2014)... TORONTO, July 10, 2014 For the first time, ... urban Aboriginal population in Canada uses health care. A ... database to clearly demonstrate the unique challenges faced by ... at St. Michael,s Hospital. , The findings, published ... between urban First Nations individuals and the general population. ...
(Date:7/9/2014)... the Perelman School of Medicine at the University of ... have received an $8 million grant from the National ... light therapy (PDT) in patients with malignant pleural mesothelioma, ... manifests itself in the lining of the lungs and ... grant will fund a clinical trial and additional studies ...
(Date:7/9/2014)... A network of signals active in almost all types ... into overdrive, and may help fuel a tumour,s uncontrolled ... of Cancer Research, London, identified a molecular trigger responsible ... the cellular factory that makes the building blocks ... in the TOR signalling pathway, called SREBP, controls the ...
(Date:7/9/2014)... Studying the most common type of lung cancer, researchers ... a role in forming tumors. The new knowledge may ... these genetic changes already are available or are in ... , investigators from The Cancer Genome Atlas (TCGA), including ... Louis, Harvard Medical School and other institutions, studied tumors ...
Breaking Medicine News(10 mins):Health News:Go play outside! Outdoor time promotes physical activity in youth 2Health News:Urban Aboriginal people face unique health challenges 2Health News:Penn mesothelioma program receives $8 million NCI grant 2Health News:Signal may send cancer's cellular factories into overdrive 2Health News:Lung cancer study hints at new treatments 2
... Reporter , MONDAY, Feb. 28 (HealthDay News) -- The battle of ... players in the fight to reduce waistlines, two new studies report. ... told by their doctors that they are overweight or obese, they ... likely to want to lose weight and to try to lose ...
... State University School of Medicine physician-researcher has developed a ... The treatment is based on a naturally occurring human ... cells into killing themselves. The unique concept, patented ... cells that are resistant to routine treatments such as ...
... Feb. 28, 2011 Los Angeles Biomedical Research ... Inc., a Japanese biotechnology firm, have entered into a ... in regenerative medicine, "Cell Sheet Engineering," LA BioMed President ... "LA BioMed is working to accelerate the pace of ...
... , A new University of Colorado Boulder study indicates ... in helping to treat people with mild traumatic brain ... U.S. war veterans returning home. The study involved ... are used to stimulate particular points on a person,s ...
... (BUSM) have found that patients with node negative T3 ... surgery had more than three times the survival rate ... appear on-line in the Journal of Thoracic and ... total of 110 patients who underwent surgical resection for ...
... brain imaging study at the U.S. Department of Energy,s (DOE) ... subjects and those who compulsively overeat, or binge: In binge ... smell of favorite foods triggers a spike in dopamine - ... - published online on February 24, 2011, in the journal ...
Cached Medicine News:Health News:Doctors Can Influence Patients to Lose Weight: Studies 2Health News:Doctors Can Influence Patients to Lose Weight: Studies 3Health News:WSU researcher creates patented personalized therapy that causes cancer cells to kill themselves 2Health News:WSU researcher creates patented personalized therapy that causes cancer cells to kill themselves 3Health News:WSU researcher creates patented personalized therapy that causes cancer cells to kill themselves 4Health News:LA BioMed and CellSeed to launch joint research project on regenerative medicine technology 2Health News:U. of Colorado study shows acupressure effective in helping to treat traumatic brain injury 2Health News:U. of Colorado study shows acupressure effective in helping to treat traumatic brain injury 3Health News:U. of Colorado study shows acupressure effective in helping to treat traumatic brain injury 4Health News:Binge eaters' dopamine levels spike at sight, smell of food 2Health News:Binge eaters' dopamine levels spike at sight, smell of food 3
... a single use rapid test, for the detection ... whole blood (venipuncture). Uni-Gold Recombigen HIV is intended ... an aid in diagnosis of infection with HIV-1. ... multi-test algorithms designed for the statistical validation of ...
... HIV-1 Oral Specimen Collection Device is a safe, ... antibodies. Testing with the OraSure HIV-1 Oral Specimen ... has been shown to be more than 99% ... cotton fiber pad attached to a nylon stick ...
The Becton™ Colles Fracture Plate has proven clinical outcomes and has excellent patient acceptance compared to external fixation. It provides a cost effective treatment option through a simple...
... Angle CHS System takes the time proven ... , ,The VHS® Supracondylar Cable Plate is ... distal femur fractures including periprosthetic fractures. The ... variable angle of the barrel and the ...
Medicine Products: